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Abstract
Objective: Chemotherapy in the last month of life for patients with metastatic lung 
cancer	 is	 often	 considered	 as	 aggressive	 end-of-life	 care.	 Targeted	 therapy	 with	
Tyrosine	Kinase	 Inhibitors	 (TKIs)	 is	 a	 relatively	 new	 treatment	 of	which	 not	much	
is known yet about use in the last month of life. We examined what percentage of 
patients	received	chemotherapy	or	TKIs	in	the	last	month	of	life	in	the	Netherlands.
Methods: Patient	files	were	drawn	from	10	hospitals	across	the	Netherlands.	Patients	
had to meet the following eligibility criteria: metastatic lung cancer; died between 
June 1, 2013 and July 31, 2015.
Results: From the included 1,322 patients, 39% received no treatment for meta-
static	lung	cancer,	52%	received	chemotherapy	and	9%	received	TKIs.	A	total	of	232	
patients	(18%)	received	treatment	in	the	last	month	of	life	(11%	chemotherapy,	7%	
TKIs).	From	the	patients	who	received	chemotherapy,	145	(21%)	received	this	in	the	
last	month	of	life	and	79	(11%)	started	this	treatment	in	the	last	month	of	life.	TKIs	
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1  | INTRODUC TION
Palliative chemotherapy, immunotherapy and targeted therapy with 
Tyrosine	Kinase	Inhibitors	(TKIs)	are	possible	treatments	for	patients	
with metastatic cancer with the aim of relieving symptoms, tempo-
rary disease control and prolonging survival. However, it is difficult to 
balance the potential clinical benefit and potential harm due to side 
effects	which	may	lead	to	a	decreased	quality	of	life	(QOL)	(Adam,	
Hug,	&	Bosshard,	2014;	Prigerson	et	al.,	2015;	Wheatley-Price	et	al.,	
2014;	Wright,	Zhang,	Keating,	Weeks,	&	Prigerson,	2014).	Moreover,	
timed discontinuation of these treatments may be essential for pa-
tients	to	prepare	for	their	death	(Adam	et	al.,	2014).	A	recent	study	
of	Bekelman	et	al.	(2016)	showed	that	up	to	12.7%	of	patients	who	
died with cancer received chemotherapy in the last 30 days of life 
(Bekelman	et	al.,	2016).	 In	2012,	 the	American	Society	 for	Clinical	
Oncology	(ASCO)	recommended	to	avoid	the	use	of	chemotherapy	
at	the	end-of-life	to	improve	patients'	care	(Schnipper	et	al.,	2012).	
Mortality within 1 month after the last chemotherapy has been con-
sidered	as	an	(negative)	indicator	of	the	quality	of	care	(Earle	et	al.,	
2008,	2003;	O'Brien	et	al.,	2006).
In case of lung cancer, whether chemotherapy near the end of life 
is	appropriate	 is	frequently	discussed	 (Yang	et	al.,	2013).	Metastatic	
lung cancer is an incurable disease associated with a high burden 
of	 symptoms,	 poor	 QOL	 and	 an	 estimated	 prognosis	 after	 the	 di-
agnosis	of	 around	1	year	 (Jemal	 et	 al.,	 2011).	According	 to	national	
and international guidelines on lung cancer, patients with lung can-
cer	 can	be	 treated	with	 chemotherapy,	 immunotherapy	 (introduced	
in	2015)	or	TKIs.	The	availability	of	new	anticancer	agents	(i.e.	TKIs)	
has prolonged the timeline of medical treatment in metastatic can-
cer	patients	(Borghaei	et	al.,	2015;	Brahmer	et	al.,	2015;	Herbst	et	al.,	
2016;	Maemondo	et	al.,	2010;	Mok	et	al.,	2017;	NSCLC	Meta-Analyses	
Collaborative	Group,	2008;	Rosell	et	al.,	2012;	Santarpia	et	al.,	2017;	
Schuler	et	al.,	2016;	Shaw	et	al.,	2013).	TKIs	are	oral	drugs	directed	
towards specific targetable protein driver mutations, such as EGFR 
and	ALK	mutations.	Multiple	clinical	trials	have	shown	that	TKIs	cause	
less side effects compared with chemotherapy and are less burden-
some	 in	 time	 and	 travelling	 for	 the	patient	 compared	 to	 in-hospital	
treatments.	Above	that,	TKIs	are	associated	with	a	5-year	survival	of	
more	than	50%	(Maemondo	et	al.,	2010;	Mok	et	al.,	2017;	Rosell	et	al.,	
2012;	Santarpia	et	al.,	2017;	Schuler	et	al.,	2016;	Shaw	et	al.,	2013).	
Therefore,	the	urgency	to	discontinue	these	drugs	in	the	last	month	of	
life may be less obvious compared with chemotherapy. Moreover, due 
to	the	expected	fast	response	of	TKIs,	starting	these	drugs	in	patients	
with a targetable driver mutation might be beneficial to their quality of 
life, especially in patients with a poor performance score.
Studies	of	Bekelman	et	al.	(2016)	and	Yang	et	al.	(2013)	reported	
respectively that within different countries 5.7%–27.7% of patients 
who died with lung cancer were treated with palliative chemotherapy 
in	 the	 last	month	of	 life	 (Bekelman	et	 al.,	 2016;	Yang	et	 al.,	 2013).	
Several studies attempt to identify the association between different 
patient characteristics and the use of palliative chemotherapy at the 
end of life. For instance, patients older than 75 years, women, unmar-
ried patients, patients with a poor performance score and patients 
with comorbidities were less likely to receive palliative chemotherapy 
for	metastatic	lung	cancer	at	the	end	of	life	(Adam	et	al.,	2014;	Choi	
et	al.,	2015;	Earle	et	al.,	2008;	Kao,	Shafiq,	Vardy,	&	Adams,	2009).	
However,	 for	TKIs	 less	 is	known	on	how	many	patients	who	die	of	
metastatic lung cancer were treated in the last month of life and 
which factors are associated with death within one month after the 
last	treatment.	A	study	among	stage	3	and	4	lung	cancer	patients	that	
started	chemotherapy	or	TKIs	as	initial	treatment	showed	that	of	pa-
tients who started chemotherapy 6.1% and of patients who started 
TKIs	 8.6%	 died	 within	 30	 days	 after	 starting	 the	 initial	 treatment	
(Burgers	&	Damhuis,	 2018).	Although	30-day	mortality	 after	 initial	
treatment is not immediately comparable to the percentage of de-
ceased patients who received treatment in the last month of life, this 
shows	that	treatment	with	TKIs	in	the	last	month	of	life	also	occurs.
In light of the above, we studied what percentage of patients 
with	metastatic	lung	cancer	receive	chemotherapy	or	TKIs	and	what	
percentage of patients receive this in the last month of life. We also 
were given and started more often in the last month of life: from the patients who 
received	TKIs,	87	(72%)	received	this	treatment	in	the	last	month	of	life	and	15	(12%)	
started this treatment in the last month of life.
Conclusion: A	substantial	percentage	of	patient	 received	and	even	started	chemo-
therapy	or	TKIs	 in	 the	 last	month	of	 life.	For	chemotherapy,	 this	might	be	seen	as	
aggressive	care.	TKIs	are	said	to	have	less	side	effects,	do	not	lead	to	many	hospital	
visits and due to the rapid response, are considered good palliation. However, it is not 
known, yet possible that, when patients still receiving treatment until shortly before 
death, this might influence preparing for death in a negative way.
K E Y W O R D S
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investigated which characteristics of patients, health care and oncol-
ogists	are	associated	with	receiving	chemotherapy	or	TKIs	in	the	last	
month of life.
2  | METHODS
2.1 | Study design and population
We have conducted a retrospective patient file study in 10 hospi-
tals	 across	 the	Netherlands,	 3	 academic	 and	7	 non-academic.	We	
extracted demographic and clinical characteristics from medical 
files of patients who died of metastatic lung cancer. Medical files 
were	 selected	 based	 on	 diagnosis	 treatment	 combinations	 (DBC)	
codes	 (DBC	 1303	 =	 Non-Small	 Cell	 Lung	 Cancer	 [NSCLC],	 DBC	
1304	=	Small	Cell	Lung	Cancer	[SCLC])	or	International	Classification	
of	Diseases	(ICD)	codes,	Ninth	and	Tenth	Revision	(ICD9	and	ICD10	
for	 (N)SCLC).	Out	of	 this	 selection,	 patients	were	 included	 if	 they	
were diagnosed with metastatic lung cancer and died between the 
1st of June 2013 and the 31st of July 2015. We excluded patients 
when they were not treated for lung cancer in the investigated hos-
pital	(n	=	123),	when	they	were	treated	with	an	experimental	drug	for	
lung	cancer	(n	=	6),	or	when	the	date	of	the	end	of	treatment	was	not	
known	(n	=	18).	A	total	of	1,322	patients	were	included	in	this	study,	
ranging from 70 till 210 patients per hospital.
2.2 | Ethics, consent and permission
This	study	was	approved	by	the	medical	ethical	committee	(METc)	of	
the	 VU	 University	Medical	 Centre	 in	 Amsterdam,	 the	 Netherlands.	
According	to	the	committee,	obtaining	informed	consent	of	the	family	
of the patients was not required since this study is based on medical 
files of patients who already died and data are handled anonymously.
2.3 | Statistical methods
Statistical analyses were conducted using IBM SPSS statistics 22. 
Differences between the demographic characteristics of the study 
participants	were	 tested	with	Analysis	of	Variance	 (ANOVA)	 for	 the	
continuous	variable	age	and	with	the	chi-square	test	for	dichotomous	
and	 nominal	 variables.	 A	 p-value	 of	 ≤.05	 denoted	 statistical	 signifi-
cance.	Generalised	estimated	equation	(GEE)	was	used	to	attain	under-
standing of the association between patient, health care and oncologist 
characteristics	and	the	use	of	chemotherapy	or	TKIs	in	the	last	month	
of life. By using the 10 hospitals as a subject variable, GEE avoids the 
cluster effect present in the commonly used logistic regression models.
The	dependent	 variable	was	 the	use	of	 chemotherapy	or	TKIs	
in	the	last	month	of	life.	This	variable	was	dichotomized	in:	“use	of	
medical	 treatment	within	1	month	before	death	 (yes/no).”	 The	 in-
dependent variables were patient, health care and oncologist char-
acteristics.	Patient	characteristics	were	sex	(male/female),	age	(≤60,	
61–70,	 ≥71),	marital	 status	 (married/unmarried),	 comorbidity	 (yes/
no),	 histology	of	 the	 tumour	 (SCLC,	NSCLC	with	 targetable	 driver	
mutation	 [NSCLC+],	 NSCLC	 without	 targetable	 driver	 mutation	
[NSCLC−])	 and	 performance	 status	 (ECOG	 [Eastern	 Cooperative	
Oncology	Group]	 score	 0,	 1,	 2,	 ≥3	 or	 not	 known).	When	 the	 per-
formance status was described using the Karnofsky score, this was 
recoded	into	the	ECOG	score	(90%–100%	=	0,	70%–80%	=	1,	50%–
60%	=	2,	30%–40%	=	3,	10%–20%	=	4).	Healthcare	characteristics	
were	 type	of	medical	 treatment	 for	metastatic	 lung	cancer	 (none/
chemotherapy/TKIs),	started	medical	treatment	in	the	last	month	of	
life	(yes/no),	line	of	medical	treatment	(first,	second,	third	and	more)	
and	hospital	type	(academic/non-academic).	Oncologist	characteris-
tics	were	sex	(male/female)	and	age	(≤40,	41–50,	≥51).
Each statistically significant variable in the univariate GEE anal-
yses	(p	<	.10)	was	entered	into	a	multivariate	GEE	model.	The	final	
model was derived using the backward selection method, with a p-
value of <.05 as considered statistically significant. Results of the 
GEE	analyses	are	presented	as	odds	ratios	(ORs)	and	associated	95%	
confidence	intervals	(CIs).
3  | RESULTS
3.1 | Patient characteristics
From the 1,322 patients with metastatic lung cancer, 509 patients 
(39%)	did	not	receive	chemotherapy	or	TKIs	for	metastatic	lung	can-
cer.	The	remaining	813	patients	received	a	systemic	treatment:	692	
patients	 received	 chemotherapy	 (52%)	 and	 121	 patients	 received	
TKIs	(9%).	The	three	groups	(no	treatment,	chemotherapy	and	TKIs)	
show a statistically significant difference on all characteristics: pa-
tients	receiving	no	treatment	had	a	higher	age	at	death	(70	±	10	years)	
compared	to	patients	receiving	chemotherapy	or	TKIs	 (65	±	9	and	
64	±	10	years	 respectively).	Moreover,	 a	higher	prevalence	of	 co-
morbidity	 was	 observed	 in	 patients	 receiving	 no	 treatment	 (81%)	
compared	with	patients	receiving	chemotherapy	or	TKIs	 (72%	and	
61%	respectively).	From	the	patients	who	received	TKIs,	41	patients	
(34%)	did	not	have	a	targetable	driver	mutation	(NSCLC−).	Only	23	
patients	with	a	 targetable	driver	mutation	 (NSCLC+)	 (5%)	 received	
no treatment. Chemotherapy was mostly administered to patients in 
the	first	line	(65%)	while	TKIs	were	mostly	administered	in	the	third	
line	(41%).	Lastly,	compared	to	patients	receiving	chemotherapy	or	
TKIs	 (65%	 and	 51%	 respectively),	 patients	 receiving	 no	 treatment	
were	found	more	often	in	a	non-academic	hospital	(78%)	(Table	1).
3.2 | Percentage of patients receiving 
chemotherapy or TKIs in the last month of life
From all 1,322 patients with metastatic lung cancer, 232 patients 
(18%)	received	chemotherapy	or	TKIs	in	the	last	month	of	life:	145	
patients	(11%)	received	chemotherapy	and	87	patients	(7%)	received	
TKIs	in	the	last	month	of	life	(Figure	1a).	From	all	the	692	patients	
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who received chemotherapy at any time for metastatic lung can-
cer, 21% received this medical treatment in the last month of life 
(Figure	1c).	From	all	the	121	patients	who	received	TKIs	at	any	time	
for metastatic lung cancer, 72% received this medical treatment in 
the	 last	month	 of	 life	 (Figure	 1b).	 From	 the	 145	 patients	who	 re-
ceived	chemotherapy	in	the	last	month	of	life,	72	patients	(50%)	only	
received	one	cycle	(data	not	shown).
We also looked at the time between initiation of the treatment and 
death: from the 692 patients who received chemotherapy at any time 
for	metastatic	 lung	 cancer,	 79	 patients	 (11%)	 died	within	 one	month	
after start of the chemotherapy. From the 121 patients who received 
TKIs	at	any	time	for	metastatic	lung	cancer,	15	patients	(12%)	died	within	
one	month	 after	 start	 of	 TKIs.	Of	 these	 15	 patients,	 8	 patients	 had	
NSCLC+	and	7	patients	had	NSCLC−.	When	treatment	was	given	in	the	
last month of life, this treatment was started in the last month of life in 
54%	in	case	of	chemotherapy	(n	=	79)	and	in	17%	in	case	of	TKIs	(n	=	15).
3.3 | Association between the characteristics of the 
population and receiving chemotherapy or TKIs in the 
last month of life
In the multivariate model, most variables were not associated with 
receiving	chemotherapy	or	TKIs	in	the	last	month	of	life,	except	for	
histology	of	the	tumour	and	type	of	treatment:	patients	with	NSCLC−	
had	a	0.439	lower	odds	(p	=	.003)	of	receiving	chemotherapy	or	TKIs	
Variable No treatmenta Chemotherapy TKIs p
 509	(39) 692	(52) 121	(9)  
Age—Years
Mean	±	SD 70	±	10 65	±	9 64	±	10 <.001
Sex
Male 313	(62) 422	(61) 56	(46)  
Female 196	(38) 270	(39) 65	(54) .006
Marital statusb
Married 298	(71) 472	(78) 93	(85)  
Not	married 123	(29) 136	(22) 17	(15) .003
ECOG performance score start
0 23	(4) 118	(17) 22	(18)  
1 57	(12) 181	(26) 33	(27)  
2 47	(10) 75	(10) 18	(15)  
≥3 65	(13) 33	(5) 9	(8)  
Not	known 300	(61) 285	(42) 39	(32) <.001
Comorbidity
Yes 409	(81) 501	(72) 72	(61)  
No 99	(19) 191	(28) 47	(39) <.001
Tumour	histology
SCLC 42	(9) 222	(32) 0	(0)  
NSCLC+ 23	(5) 79	(11) 80	(66)  
NSCLC− 412	(86) 390	(56) 41	(34) <.001
Line	of	treatment
1st	(490)  451	(65) 39	(33)  
2nd	(185)  154	(22) 31	(26)  
≥	3rd	(134) N.A. 85	(12) 49	(41) <.001
Hospital type
Academic 113	(22) 242	(35) 59	(49)  
Non-academic 396	(78) 450	(65) 62	(51) <.001
Note: Bold values indicate a p-value	<.05.	
Abbreviations:	ECOG,	Eastern	Cooperative	Oncology	Group;	SCLC,	small	cell	lung	cancer;	
N.A.,	not	applicable;	NSCLC,	non-small	cell	lung	cancer;	NSCLC+,	NSCLC	with	targetable	driver	
mutation;	NSCLC−,	NSCLC	without	targetable	driver	mutation;	TKIs,	Tyrosine	Kinase	Inhibitors.
aNo	treatment	is	defined	as	receiving	no	chemotherapy	or	TKIs	for	metastatic	lung	cancer.	
b>5%	missing	values:	marital	status	(14%).	
TA B L E  1   Demographic characteristics 
of	study	participants	(n	=	1,322,	column	
%)
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in	the	 last	month	of	 life	compared	to	patients	with	SCLC.	Patients	
receiving	TKIs	had	a	9.503	higher	odds	 (p	<	 .001)	of	receiving	this	
treatment in the last month of life, compared to patients receiving 
chemotherapy	(Table	2).	Therefore,	we	decided	to	do	a	separate	GEE	
analysis	for	patients	receiving	chemotherapy	and	TKIs.	From	these	
patients	 receiving	TKIs	 in	 the	 last	month	of	 life,	25	patients	 (29%)	
had	NSCLC−	(data	not	shown).
3.4 | Association between the characteristics of the 
population and receiving chemotherapy in the last 
month of life
Histology of the tumour and line of treatment were associated 
with receiving chemotherapy in the last month of life. Patients with 
NSCLC−	 had	 a	 0.468	 lower	 odds	 (p	 =	 .009)	 of	 receiving	 chemo-
therapy	 in	 the	 last	month	of	 life	compared	 to	patients	with	SCLC.	
Patients	who	received	third-line	chemotherapy	had	a	2.016	higher	
odds	(p	=	.013)	of	receiving	chemotherapy	in	the	last	month	of	life	
compared	to	patients	receiving	first-line	chemotherapy	(Table	3).
3.5 | Association between the characteristics of the 
population and receiving TKIs in the last month of life
Tumour	histology,	line	of	treatment	and	age	of	the	oncologist	were	
associated	 with	 receiving	 TKIs	 in	 the	 last	 month	 of	 life.	 Patients	
with	NSCLC+	had	a	2.529	higher	odds	(p	=	 .001)	of	receiving	TKIs	
in	the	last	month	of	life	compared	to	patients	with	NSCLC−.	Patients	
who	received	TKIs	in	the	last	month	of	life	had	a	1.723	higher	odds	
(p	=	 .042)	of	receiving	this	 in	the	second	 line	than	 in	the	first	 line.	
From	the	patients	who	received	TKIs	in	the	second	line,	15	patients	
(48%)	had	NSCLC−.	From	the	patients	who	received	TKIs	in	the	third	
line,	19	patients	(39%)	had	NSCLC−.	Patients	with	a	prescribing	on-
cologist	in	the	age	range	of	≤40	and	41–50	had	respectively	a	3.238	
and	2.841	higher	odds	(p	=	.036;	p	=	.027)	of	receiving	TKIs	in	the	last	
month of life compared to patients with a prescribing oncologist in 
the	age	range	of	≥51	(Table	4).
4  | DISCUSSION
From the 1,322 patients included in this study, 39% received no 
treatment for metastatic lung cancer, 52% received chemotherapy 
and	9%	received	TKIs.	In	total,	18%	received	treatment	in	the	last	
month	of	life	(11%	chemotherapy	and	7%	TKIs).	When	treatment	
was	given,	TKIs	were	(still)	given	more	often	in	the	last	month	of	
life	than	chemotherapy	(72%	vs.	21%).	When	treatment	was	(still)	
given in the last month of life, this treatment was started in the 
last month of life in 54% in case of chemotherapy and in 17% in 
case	of	TKIs.
Our study found a percentage of patients receiving chemo-
therapy in the last month of life that falls within the range of rates 
found	 for	 patients	 with	 lung	 cancer	 in	 other	 studies	 (between	
F I G U R E  1   Percentages of patients 
receiving medical treatment 11%
41%
7%2%
39%
Chemotherapy in the
last month
Chemotherapy not in
the last mont
TKIs in the last month
TKIs not in the last
month
No treatment
72%
28%
Patients receiving TKIs (%) n = 121
Treatment in the last month of life
No treatment in the last month of life
21%
79%
Patients receiving chemotherapy (%) n = 692
Treatment in the last month of life
No treatment in the last month of life
(a)
(c)(b)
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5.7%	and	27.7%)	 (Bekelman	 et	 al.,	 2016;	Yang	 et	 al.,	 2013).	 The	
rate	of	11%	that	we	found	for	the	Netherlands	is	somewhat	lower	
than	the	one	of	16.4%	found	by	Bekelman	et	al.	(2016).	This	might	
be due to the difference in methods; making use of administrative 
claims data as they did in that study gives less precise informa-
tion on the exact date a treatment is started or stopped than a 
patient	 file	 study.	 The	 percentages	 found	 in	 both	 studies	 show	
that	the	Netherlands	are	not	among	the	countries	with	the	lowest	
N = 813
Variable (N)
Patients receiving 
medical treatment 
in the last month 
of life (row %)
Univariate
OR (95% CI)
Multivariate
OR (95% CI)
Sex
Female	(335) 31 1.068	(0.923–1.236)  
Male	(478) 27 1.0  
Age—Years
≤60	(231) 32 1.308	(0.949–1.801)  
60–71	(318) 29 1.147	(0.827–1.590)  
≥71	(264) 25 1.0  
Marital status
Not	married	
(153)
26 1.0  
Married	(565) 30 1.162	(0.740–1.825)  
Comorbidity
No	(238) 20 1.014	(0.657–1.566)  
Yes	(573) 16 1.0  
Tumour	histology
SCLC	(222) 29 1.0 1.0
NSCLC+	(159) 51 2.212 (1.163–4.210)* 0.817	(0.284–2.350)
NSCLC−	(431) 20 0.593 (0.390–0.92)* 0.439 (0.257–0.751)**
Line	of	treatment
1st	(490) 22 1.0  
2nd	(185) 31 1.560 (1.219–1.997)*  
≥	3rd	(134) 46 2.510 (1.528–4.123)*  
Sex oncologist
Female	(196) 26 1.0  
Male	(575) 29 1.105	(0.668–1.829)  
Age	category	oncologist
≤	40	(106) 33 1.129	(0.701–1.819)  
41–50	(296) 26 0.945	(0.579–1.541)  
≥	51	(369) 29 1.0  
Hospital type
Academic	(301) 35 1.435	(0.622–3.308)  
Non-academic	
(512)
25 1.0  
Type	of	treatment
Chemotherapy 
(692)
21 1.0 1.0
TKIs	(121) 72 8.182 (5.694–11.756)* 9.503 (5.156–17.517)**
Abbreviations:	NSCLC,	non-small	cell	lung	cancer;	NSCLC+,	NSCLC	with	targetable	driver	
mutation;	NSCLC−,	NSCLC	without	targetable	driver	mutation;	OR,	odds	ratio;	SCLC,	small	cell	lung	
cancer;	TKIs,	Tyrosine	Kinase	Inhibitors.
*p-Value	of	≤.10.	
**p-Value	of	≤.05	
TA B L E  2  Univariate	and	multivariate	
GEE analyses of factors associated with 
receiving	chemotherapy	or	TKIs	within	
1 month before death
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percentages	such	as	Canada	 (5.9%)	or	Norway	 (5.7%)	 (Bekelman	
et	al.,	2016).
To	our	knowledge	there	are	no	studies	with	which	we	can	com-
pare our finding of 7% of patients who died with metastatic lung 
cancer	that	had	TKIs	in	the	last	month	of	life.	This	percentage	seems	
low,	but	this	is	for	a	large	part	due	to	TKIs	not	being	given	so	often	
to	this	patient	group	 (9%	TKIs	and	52%	chemotherapy).	We	found	
that	 patients	 who	 received	 TKIs	 had	 an	 odds	 ratio	 of	 9.5	 to	 still	
receive therapy in the last month of life compared to patients re-
ceiving	chemotherapy.	A	salient	finding	is	that	from	patients	receiv-
ing	TKIs	 in	 their	 last	month,	 71%	did	not	 have	 a	 targetable	driver	
mutation.	However,	these	patients	did	not	receive	their	TKIs	in	the	
first line. Knowing the rate of success is low in this group, it is de-
batable	whether	 this	 should	 be	 considered	 good	 practice	 (Corallo	
N = 692
Variable (N)
Patients 
receiving medical 
treatment in the 
last month of life 
(row %)
Univariate
OR (95% CI)
Multivariate
OR (95% CI)
Sex
Female	(270) 22 1.085	(0.814–1.445)  
Male	(422) 20 1.0  
Age—years
≤60	(188) 22 1.204	(0.756–1.918)  
61–70	(270) 22 1.198	(0.824–1.741)  
≥71	(234) 19 1.0  
Marital status
Not	married	
(136)
21 1.018	(0.660–1.572)  
Married	(472) 22 1.0  
Comorbidity
No	(191) 19 1.0  
Yes	(501) 22 1.208	(0.702–2.080)  
Tumour	histology
SCLC	(222) 29 1.0 1.0
NSCLC+	(79) 24 0.563	(0.238–1.329) 0.664	(0.216–2.043)
NSCLC−	(390) 16 0.442 (0.277–0.704)* 0.468 (0.265–0.828)**
Line	of	treatment
1st	(451) 18 1.0 1.0
2nd	(154) 21 1.243	(0.831–1.861) 1.050	(0.646–1.709)
≥	3rd	(85) 34 2.072 (1.287–3.336)* 2.016 (1.157–3.513)**
Sex oncologist
Female	(178) 20 1.0  
Male	(484) 21 1.095	(0.764–1.571)  
Age	category	oncologist
≤	40	(91) 24 1.205	(0.775–1.873)  
41–50	(263) 19 0.885	(0.576–1.360)  
≥	51	(307) 22 1.0  
Hospital type
Academic	(242) 25 1.357	(0.605–3.042)  
Non-academic	
(450)
19 1.0  
Abbreviations:	NSCLC:	non-small	cell	lung	cancer;	NSCLC+:	NSCLC	with	targetable	driver	
mutation;	NSCLC−:	NSCLC	without	targetable	driver	mutation;	OR:	odds	ratio;	SCLC:	small	cell	
lung	cancer;	TKIs:	Tyrosine	Kinase	Inhibitors.
*p-Value	of	≤.10.	
**p-Value	of	≤.05	
TA B L E  3  Univariate	and	multivariate	
GEE analyses of factors associated with 
receiving chemotherapy within 1 month 
before death
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et	al.,	2017).	This	 result	 resonates	with	 findings	of	Choi	et	al.	 that	
the	time	between	stopping	TKIs	and	death	is	shorter	compared	to	
the time between stopping chemotherapy and death: being 19 days 
compared	to	35	days	respectively	 (Choi	et	al.,	2015).	Burgers	et	al	
also	 found	 a	 higher	 odds	 (OR	=	1.3)	 of	 TKIs	 compared	 to	 chemo-
therapy	with	regard	to	30-day	mortality	after	the	start	of	the	initial	
treatment	(Burgers	&	Damhuis,	2018).
Tyrosine	Kinase	 Inhibitors	are	believed	to	extend	survival	with	
less toxicity and a higher quality of life in patients with a specific 
targetable protein driver mutation. If effective, they usually show a 
rapid response which makes it suitable for patients with a poor per-
formance	score.	Therefore,	oncologists	may	be	reluctant	to	stop	this	
medication	even	when	it	is	close	to	the	end	of	life.	Another	reason	
of	reluctance	to	stop	might	be	that	a	disease	flare	after	TKIs	discon-
tinuation	may	occur	(Chaft	et	al.,	2011).	Although	nausea,	vomiting,	
myelosuppression and alopecia generally occur less frequently than 
with	 chemotherapy,	 TKIs	 are	 associated	with	 side	 effects	 such	 as	
skin problems, chronic diarrhoea, fatigue and electrolyte imbalances 
N = 121
Variable (N)
Patients receiving 
medical treatment 
in the last month of 
life (row %)
Univariate
OR (95% CI)
Multivariate
OR (95% CI)
Sex
Female	(65) 65 0.436 (0.201–0.945)*  
Male	(56) 80 1.0  
Age—Years
≤60	(43) 74 1.033	(0.317–3.361)  
61–70	(48) 69 0.773	(0.282–2.116)  
≥71	(30) 73 1.0  
Marital status
Not	married	(17) 65 1.0  
Married	(93) 73 1.496	(0.426–5.253)  
Tumour	histology
NSCLC+	(80) 79 2.211 (1.242–3.934)* 2.529 (1.448–4.639)**
NSCLC−	(41) 61 1.0  
Comorbidity
No	(47) 70 1.0  
Yes	(72) 72 1.102	(0.586–2.071)  
Line	of	treatment
1st	(39) 72 1.0 1.0
2nd	(31) 81 1.670 (1.025–2.719)* 1.723 (1.019–2.912)**
≥	3rd	(49) 67 0.836	(0.343–2.047) 1.188	(0.520–2.712)
Sex oncologist
Female	(18) 83 1.775	(0.846–3.723)  
Male	(91) 73 1.0  
Age	category	oncologist
≤	40	(15) 87 3.553 (1.106–11.414)* 3.238 (1.081–9.698)**
41–50	(33) 85 2.848 (1.068–7.599)* 2.841 (1.123–7.184)**
≥	51	(62) 66 1.0 1.0
Hospital type
Academic	(59) 75 1.374	(0.712–2.641)  
Non-academic	
(62)
70 1.0  
Abbreviations:	OR:	odds	ratio;	TKIs:	Tyrosine	Kinase	Inhibitors;	SCLC:	small	cell	lung	cancer;	
NSCLC:	non-small	cell	lung	cancer;	NSCLC+:	NSCLC	with	targetable	driver	mutation;	NSCLC−:	
NSCLC	without	targetable	driver	mutation.
*p-Value	of	≤.10.	
**p-Value	of	≤.05	
TA B L E  4  Univariate	and	multivariate	
GEE analyses of factors associated with 
receiving	TKIs	within	1	month	before	
death
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that	 should	 not	 be	 ignored	 (Guevremont,	 Alasker,	 &	 Karakiewicz,	
2009).	The	risk	of	side	effects	may	also	increase	closer	to	the	end	of	
life due to altered metabolism and interaction with other prescribed 
medication	 (Burotto,	Ali,	&	O'Sullivan	Coyne,	2015).	On	 the	other	
hand,	in	a	study	of	Shaw	et	al.	(2013),	patients	reported	greater	re-
ductions in symptoms of lung cancer and greater improvement in 
global	quality	of	life	with	crizotinib	(a	TKI)	than	with	chemotherapy	
(Shaw	et	al.,	2013).	However,	even	with	a	five-year	survival	of	>50%,	
timely discontinuation of these treatments may be essential to pa-
tients	for	a	dignified	leave	of	their	loved	ones	and	life	itself	(Adam	
et	al.,	2014).	Therefore,	more	research	is	needed	about	the	conse-
quences	of	continuation	of	TKIs	shortly	before	death.	Only	then	it	
is	possible	to	consider	whether	not	giving	TKIs	shortly	before	death	
should	be	a	quality	 indicator	 for	appropriate	end-of-life	care,	as	 is	
not	giving	chemotherapy	shortly	before	death	(De	Roo	et	al.,	2014).	
Our result, that in 54% of patients who received chemotherapy in 
the last month of their life this treatment also had started in the last 
month of life, is an indication of overtreatment and supports the rel-
evance	of	this	quality	indicator	and	the	recommendations	of	ASCO	
(Schnipper	et	al.,	2012).
Patients	 who	 received	 third-line	 chemotherapy	 had	 higher	
odds	 (OR	=	2.084)	 of	 receiving	 chemotherapy	 in	 the	 last	month	
of	 life	compared	with	patients	 receiving	 first-line	chemotherapy.	
In this case, it might play a role that patients with already a poor 
performance status were given chemotherapy as a final option for 
maintaining hope and therefore died shortly after the last chemo-
therapy	cycle.	SCLC	patients	may	have	received	chemotherapy	for	
attempted symptom control, which might explain the lower odds 
of	NSCLC	patients	 receiving	chemotherapy.	Patients	with	a	pre-
scribing	oncologist	aged	≤50	had	a	higher	odds	of	receiving	TKIs	
in the last month of life compared to patients with a prescribing 
oncologist	aged	≥51.	A	possible	explanation	might	be	that	younger	
oncologists are better up to date compared to their older col-
leagues	when	it	comes	to	TKIs.
The	high	number	of	patients	analysed	in	this	study	(1,322)	among	
ten different hospital sites makes the results robust and generaliz-
able. Since all patients diagnosed with metastatic lung cancer were 
included in this study, there is no selection bias. However, this study 
has some potential limitations. First, the inevitable limitation of a 
patient file study is that we are not able to discover the rationale 
of the patient and the oncologist behind starting and stopping of 
chemotherapy	or	TKIs.	 Second,	data	on	performance	 status	 could	
not always be retrieved from medical records due to the absence of 
documentation.	Third,	we	only	documented	the	last	treatment	line;	
therefore, we do not know what treatments patients received in ear-
lier treatment lines.
In conclusion, our study gives indications of overtreatment at 
the	end	of	life.	An	indicator	is	that	more	than	half	of	patients	who	
received chemotherapy in the last month of life also started this 
treatment	in	the	last	month	of	life.	Also	that	the	choice	of	the	treat-
ment	 among	 others	 depends	 on	 non-patient-related	 factors	 such	
as age of the oncologist might be an indication of overtreatment. 
Additionally,	a	high	percentage	of	patients	treated	with	TKIs	did	not	
fulfil appropriate criteria for starting this type of treatment, which 
might indicate overtreatment of negative driver mutation patients. 
Especially when chemotherapy is started shortly before death, this 
can	be	seen	as	aggressive	care.	TKIs	are	said	to	have	less	side	effects	
and	do	not	 lead	 to	many	hospital	 visits.	 Therefore,	 it	 is	 debatable	
whether	TKIs	started	shortly	before	death	should	be	considered	as	
aggressive treatment. However, when still receiving it until shortly 
before death, this might influence preparing for death in a negative 
way.	It	is	important	to	study	whether	this	is	the	case.	Although	this	
study describes the Dutch situation, the percentages of receiving 
a medical treatment for metastatic lung cancer are informative for 
other countries.
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